

Hematology
 Measure#3: Multiple Myeloma: Treatment with Bisphosphonates

This measure may be used as an Accountability measure

Clinical Performance Measure
<p>Numerator: Patients who were prescribed* or received intravenous bisphosphonate therapy** within the 12 month reporting period</p> <p>Definition: *Prescribed: Includes patients who are currently receiving medication (ts</p> <p>Definition: Reason(s) for not prescribing bisphosphonates (eg, patients who do</p> <p style="text-align: right;">not</p> <p>have bone disease patients with dental disease patients with renal insufficiency)</p> <p>Documentation of patient reason(s) for not prescribing bisphosphonates</p> <p>Measure Description: Percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed or received intravenous bisphosphonate therapy within the 12 month reporting period</p>

The following clinical recommendation statements are quoted verbatim from the referenced clinical guidelines and represent the evidence base for the measure

Rationale for the measure:

Multiple myeloma is a disease characterized by bone destruction, in the form of diffuse osteopenia and/or osteolytic lesions, which develop in a significant number of patients. Bisphosphonates can inhibit bone resorption by reducing the number and activity of osteoclasts.

Bisphosphonates have played an important palliative role in the care of patients with multiple myeloma. Use of these agents has demonstrated benefit in reducing painful bony complications.

Measure Specifications Measure #3: Multiple Myeloma Treatment with Bisphosphonates

Administrative Claims/Registry

Administrative claims data collection requires users to identify the eligible population (denominator) and numerator using codes recorded on claims or billing forms (electronic or paper). Users report a rate based on all patients in a given practice for whom data are available and who meet the eligible population/denominator criteria.

Denominator (Eligible Population) All patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission